Alnylam Pharmaceuticals, Inc.

ALNY Healthcare Biotechnology

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue grew 66.9%, EPS grew 341.2%, free cash flow grew 152.8% and total debt fell 1.51%, each against the same quarter a year earlier. Member of the Nasdaq 100; revenue growth for five consecutive years.

231.83 2.20 −0.94%
Market cap
$31.3B
P/E
39.5×
Fwd P/E
39.6×
Dividend yield
—
F-score
6/9
Altman Z
7.30
Beneish M
−1.95
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
6 5 5 3 3 4 2 2 5 2
P/E ratio
163.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
14.03 13.36 13.32 27.40 23.79 30.32 57.26 97.91 132.79 70.13
Altman Z-Score
7.30 2.90 1.84 2.30 2.14 1.92 5.20 12.72 28.92 3.22
Altman Z″-Score (non-manufacturers)
(0.11) (2.60) (3.07) (4.01) (2.17) (1.67) (2.40) (0.09) 8.26 (0.91)
P/FCF ratio
111.94 0.00 580.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/Operating CF
318.51 (317.31) (817.18) (215.38) (133.79) (121.36) (64.21) (48.74) (115.87) (42.22)
Beneish M-Score
(1.95) (2.50) (2.66) (3.07) (3.03) 3.21 (1.52) (3.71) (2.25) (2.03)
P/B ratio
66.01 447.73 0.00 0.00 34.15 14.71 8.75 5.63 6.76 3.59
Price to Tangible BV
66.01 447.73 0.00 0.00 34.15 14.71 8.75 5.63 6.76 3.59
EV/Sales
13.51 12.62 12.54 26.27 21.71 26.91 51.53 83.83 114.32 60.02
EV/EBITDA
90.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
95.77 (3,412.86) 220.14 (50.34) (28.56) (21.56) (40.67) (11.16) (26.85) (9.20)
EV/FCF
107.85 (666.08) 546.65 (44.43) (25.52) (19.35) (27.05) (9.11) (21.11) (7.60)
Quick Ratio
2.51 2.61 2.86 3.16 3.79 4.23 4.48 6.14 11.96 4.94
Current Ratio
2.76 2.78 3.08 3.51 4.04 4.47 4.87 6.69 12.23 5.10
Net Debt/EBITDA
(3.41) 13.89 6.22 1.59 2.84 2.23 1.42 1.32 3.40 1.16
Debt/Assets
20.29% 24.17% 26.65% 28.68% 18.55% 5.61% 11.52% 1.91% 1.50% 11.88%
Debt/Equity
1.28 15.27 (4.63) (6.43) 1.15 0.19 0.19 0.02 0.02 0.16
Asset Turnover
0.81 0.56 0.50 0.29 0.24 0.17 0.11 0.04 0.06 0.04
Operating CF/Net income
1.67 0.03 (0.24) 0.48 0.75 0.72 0.31 0.74 0.78 0.75
Capex/Depreciation
(1.05) (0.60) (1.15) (1.62) (0.85) (0.95) (2.58) (8.32) (8.76) (4.27)
Interest Coverage
1.99 (1.25) (2.33) (5.03) (4.95) (9.80) (28.47) (28.09) (40.87) (51.11)
ROE
73.28% 362.29% 232.40% (526.14%) (106.31%) (69.92%) (64.66%) (49.63%) (36.54%) (37.54%)
ROA
6.82% (6.89%) (11.94%) (31.47%) (24.19%) (29.58%) (44.64%) (42.67%) (30.14%) (30.96%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% (328.88%) (205.47%) (295.38%) (59.85%)
Return on Tangible Assets
10.13% (10.65%) (17.33%) (46.21%) (32.61%) (34.41%) (49.55%) (56.75%) (27.23%) (62.64%)
Average Days of Receivables
76.42 65.80 65.44 83.72 85.85 446.14 71.44 91.41 138.03 180.60
Research and Development Expense of Revenue
35.54% 50.09% 54.94% 85.12% 93.83% 132.86% 298.12% 674.72% 434.46% 810.86%
Selling, General and Administrative Expense of Revenue
32.60% 43.39% 43.52% 74.29% 73.51% 119.39% 217.98% 510.44% 221.73% 189.47%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
9.38% 12.10% 12.12% 22.23% 19.63% 28.38% 79.56% 210.59% 103.23% 160.16%
Graham Net Nets
0.00 (0.03) (0.04) (0.04) (0.01) 0.02 0.06 0.13 0.13 0.10
Graham Number
18.18 0.00 11.84 16.49 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
0.61% (0.92%) (1.81%) (3.98%) (4.25%) (5.73%) (7.07%) (10.37%) (4.10%) (12.40%)
Free Cash Flow Yield
0.89% (0.14%) 0.17% (2.16%) (3.57%) (4.59%) (3.33%) (9.40%) (4.08%) (11.26%)
Revenue per Share
28.35 17.61 14.64 8.53 7.13 4.29 2.01 0.74 0.99 0.55
Operating CF per Share
4.00 (0.07) 0.83 (4.45) (5.42) (5.35) (2.55) (5.59) (4.23) (3.59)
Capex per Share
(0.45) (0.27) (0.50) (0.59) (0.64) (0.61) (1.28) (1.26) (1.15) (0.75)
Free Cash Flow per Share
3.55 (0.33) 0.34 (5.04) (6.06) (5.96) (3.83) (6.85) (5.38) (4.35)
Cash per Share
22.20 21.11 19.53 18.02 20.56 16.30 14.06 10.78 18.67 7.32
Shareholders Equity per Share
6.02 0.53 (1.77) (1.30) 4.97 8.84 13.17 12.94 19.51 10.75
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
6.02 0.53 (1.77) (1.30) 4.97 8.84 13.17 12.94 19.51 10.75
Free Cash Flow
465.38 (42.59) 41.95 (613.33) (718.06) (685.32) (418.58) (689.50) (486.99) (372.26)
Working Capital
2,584.31 2,109.01 2,014.91 1,924.33 2,112.87 2,029.51 1,363.27 1,021.20 1,620.49 540.18
Capital Expenditures
(58.70) (34.28) (62.21) (72.06) (76.37) (70.36) (140.16) (126.89) (104.21) (64.56)
Net Current Asset Value
(126.49) (877.61) (1,067.83) (1,012.33) (246.52) 223.96 759.42 927.86 1,536.44 329.29
EV/EBIT
100.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.02 0.02 0.03 0.07 0.09 0.14 0.64 1.69 1.16 1.37
Price to Operating Income
103.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.11 0.11 0.10 0.08 0.18 0.16 0.13 0.05 0.07 0.13
Cash ROIC
9.89% (1.12%) 1.29% (20.10%) (19.41%) (22.24%) (12.88%) (28.54%) (13.97%) (21.94%)
Accounts Receivable Turnover
6.28 6.13 6.46 4.75 2.11 1.53 7.12 2.84 3.14 2.98
Accounts Payable Turnover
6.68 4.49 4.04 1.97 2.24 1.53 0.46 0.04 0.00 0.00
Inventory Turnover
8.46 3.86 2.85 1.57 1.73 1.19 0.62 0.05 — —
Average Days of Payables
61.94 99.80 65.28 212.09 191.24 243.01 726.50 12,094.02 0.00 0.00
Days of Inventory on Hand
44.28 88.62 104.82 278.83 224.93 351.67 820.65 4,875.04 — —
Average Receivables
591.44 366.55 282.88 218.27 400.49 322.71 30.89 26.38 28.67 15.82
Average Payables
102.07 71.97 76.81 85.76 62.70 50.93 54.80 44.03 41.41 35.63
Average Inventory
80.61 83.83 109.05 107.66 80.78 65.78 40.21 40.00 — —
Average Assets
4,603.16 4,034.93 3,688.12 3,594.83 3,525.18 2,901.10 1,984.97 1,784.77 1,628.77 1,324.66
Average Common Equity
428.13 (76.78) (189.43) 214.99 802.23 1,227.47 1,370.33 1,534.20 1,343.33 1,092.47

Fold the line items

Columns are period end dates